NEW YORK, Oct. 29 – Atto BioScience, a Rockville, Md.-based biotech company,  has raised $3 million in its first round of private equity financing, the company said on Monday.

Emerging Technology Partners led the financing round.

The capital will help Atto to finish the development and commercialization of its first high-throughput single-cell-imaging system. This system, scheduled to launch later this year, was developed in collaboration with a major US pharmaceutical company, Atto said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.